192069-85-5

Basic information

• Product Name: 4-Piperidinecarbonitrile, 4-(4-fluorophenyl)-1-(phenylmethyl)-
• CAS NO: 192069-85-5
• Molecular Formula: C19H19FN2
• Molecular Weight: 294.372
• Mol File: 192069-85-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-Piperidinecarbonitrile, 4-(4-fluorophenyl)-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinecarbonitrile, 4-(4-fluorophenyl)-1-(phenylmethyl)-(192069-85-5)
• EPA Substance Registry System: 4-Piperidinecarbonitrile, 4-(4-fluorophenyl)-1-(phenylmethyl)-(192069-85-5)

Safety Data

• Hazardous Substances Data: 192069-85-5(Hazardous Substances Data)

Upstream product

• 459-22-3 4-fluorophenylacetonitrile 
• 10429-82-0 N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine hydrochloride 
• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 

Downstream Products

• 1278403-47-6 1-benzyl-4-(4-fluorophenyl)piperidine-4-carboxylic acid 
• 1146362-41-5 [1-benzyl-4-(4-fluorophenyl)-piperidin-4-yl]-(4-fluorophenyl)-methanone 
• 252002-46-3 4-(4-fluorophenyl)piperidine-4-carbonitrile 
• 214848-27-8 1-Benzyl-4-(4-fluoro-phenyl)-1-oxy-piperidine-4-carboxylic acid amide 

Relevant articles and documents

Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors

A series of novel pyrazol-furan carboxamide analogues were designed, synthesized and biologically evaluated for their Akt1 inhibitory activities, as well as anti-proliferative efficacies against HCT116 and OVCAR-8 cell lines. Most compounds exhibited mode

SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 may have the meanings given in claim 1, as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists

We recently described the synthesis and characterization of MDL 105,212, a non peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors. Here we report the synthesis and structure-activity relationships for a series of analogs of MDL 105,212 with regards to: NK1 and NK2 receptor binding affinity, physical-chemical characterization; in vitro absorption potential; in vitro metabolic stability; and efficacy in a capsaicin-challenge conscious guinea pig model after oral administration.